Table 2.
Role of the modifier in cancer
| Type of cancer | Role of the modifier | m6A(methylation) modifier |
|---|---|---|
| Breast cancer | Oncogene | METTL5, WTAP, VIRMA, ZNF217, FTO, ALKBH5, ELAVL1, YTHDF1/2/3, IGF2BP1/2/3, HNRNPs |
| Tumor suppressor | ZC3H13, HAKAI | |
| Bivalent | METTL3/14 | |
| Lung Cancer | Oncogene | METTL3/5, WTAP, VIRMA, HAKAI, FTO, ELAVL1, YTHDF1, IGF2BP1/3, HNRNPs |
| Tumor suppressor | METTL14, YTHDC2 | |
| Bivalent | ALKBH5, YTHDF2, IGF2BP2 | |
| Prostate cancer | Oncogene | VIRMA, ZNF217, ELAVL1, YTHDF2, IGF2BP2, HNRNPs |
| Tumor suppressor | FTO | |
| Bivalent | METTL3 | |
| Colorectal cancer | Oncogene | WTAP, ZNF217, HAKAI, ELAVL1, YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3, HNRNPs, FTO |
| Tumor suppressor | METTL14, ZC3H13 | |
| Bivalent | METTL3, ALKNH5 | |
| Gastric cancer | Oncogene | METTL3/16, WTAP, VIRMA, ZNF217, ALKBH5, ELAVL1, YTHDF1, IGF2BP1/2/3, HNRNPs |
| Tumor suppressor | METTL14, YTHDF2 | |
| Bivalent | FTO | |
| Liver cancer | Oncogene | METTL3, WTAP, VIRMA, ZNF217, FTO, YTHDF1/3, YTHDC2, IGF2BP1/2/3, HNRNPs |
| Tumor suppressor | METTL14 | |
| Bivalent | ALKBH5, ELAVL1, YTHDF2 | |
| Cervical cancer/ endometrial cancer/ ovarian cancer | Oncogene | ZNF217, WTAP, FTO, ALKBH5, YTHDF1, IGF2BP1/2/3, HNRNPs, ELAVL1, YTHDF2 |
| Bivalent | METTL3, YTHDF2 | |
| Esophageal cancer | Oncogene | METTL3, WTAP, FTO, ELAVL1, IGF2BP1/2/3, HNRNPs |
| Bivalent | ALKBH5 | |
| Thyroid cancer | Oncogene | METTL14, IGF2BP1/2/3 |
| Tumor suppressor | FTO | |
| Bivalent | METTL3 | |
| Bladder cancer | Oncogene | METTL3, WTAP, YTHDF2, IGF2BP1 |
| Tumor suppressor | METTL14, ALKBH5 | |
| Bivalent | FTO | |
| Pancreatic cancer | Oncogene | METTL3/14, WTAP, YTHDF2, IGF2BP2/3, HNRNPs |
| Tumor suppressor | FTO, ALKBH5, YTHDC1 | |
| Leukaemia | Oncogene | METTL3/14, WTAP, FTO, ALKBH5, YTHDF2, IGF2BP1/2/3, RBM15 |
| Kidney cancer | Oncogene | WTAP, IGF2BP1/3, HNRNPs |
| Tumor suppressor | METTL14, FTO, YTHDF2 | |
| Bivalent | ALKBH5 | |
| Melanoma | Oncogene | METTL3, FTO, ALKBH5, ELAVL1, YTHDF1/2, IGF2BP1/2/3, HNRNPs |
| Head and neck cancer | Oncogene | METTL3, FTO, ALKBH5, ELAVL1, YTHDF1, IGF2BP1/2//3, HNRNPs |
| Bivalent | YTHDC2 | |
| Glioblastoma | Oncogene | METTL3, ZNF217, ALKBH5, ELAVL1, YTHDF1/2, IGF2BP1/2/3 |
| Osteosarcoma | Oncogene | METTL14, ZNF217, ELAVL1, IGF2BP1 |
| Tumor suppressor | YTHDF2 | |
| Bivalent | ALKBH5 | |
| Cholangiocarcinoma/ gallbladder cancer | Oncogene | IGF2BP1/2 |
| Tumor suppressor | FTO, ALKBH5 | |
| Retinoblastoma | Oncogene | METTL3, IGF2BP1 |
| lymphomas | Oncogene | METTL3/14, WTAP, RBM15, FTO, ALKBH5, YTHDF2, IGF2BP1/2/3 |
| Rhabdomyosarcoma | Oncogene | IGF2BP1 |
| Seminoma | Oncogene | METTL3 |
| Thymic epithelial cancer | Oncogene | METTL3 |
See Additional file 1: Table S1 for detailed references